(NASDAQ: RNA) Atrium Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.94%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 36.33%.
Atrium Therapeutics's earnings in 2026 is -$49,501,000.On average, 2 Wall Street analysts forecast RNA's earnings for 2026 to be -$64,874,279, with the lowest RNA earnings forecast at -$62,947,320, and the highest RNA earnings forecast at -$67,443,557. On average, 2 Wall Street analysts forecast RNA's earnings for 2027 to be -$72,395,934, with the lowest RNA earnings forecast at -$70,245,560, and the highest RNA earnings forecast at -$75,263,100.
In 2028, RNA is forecast to generate -$19,066,342 in earnings, with the lowest earnings forecast at -$52,760,193 and the highest earnings forecast at $24,761,886.